T cell responses to CD1-restricted lipids in tuberculosis

结核病中 T 细胞对 CD1 限制性脂质的反应

基本信息

  • 批准号:
    8610867
  • 负责人:
  • 金额:
    $ 44.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-03-01 至 2016-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant: M. tuberculosis remains a pathogen of global importance, currently infecting 1.6 billion people, killing 1.7 million annually. Successful human responses to infection depend critically on T cells, which were previously thought to be activated solely by peptide antigens bound to MHC proteins. However, CD1 proteins represent a newly discovered pathway for activation of T cells by mycobacteria and other pathogens. CD1 proteins are expressed in a highly regulated fashion on dendritic cells, where they capture mycobacterial lipid antigens for presentation to T cells. CD1 proteins are present in all mammals, so likely have an indispensable function in immune response. Although the basic functions of CD1d and NK T cells are becoming well understood, the natural functions of human CD1a, CD1b and CD1c proteins are not yet known. After discovering lipid antigens presented by CD1a (dideoxymycobactin), CD1b (glucose monomycolate) and CD1c (mannosyl phoshomycoketide), this renewal proposal uses a well developed model system to determine for the first time the general molecular mechanisms by which these antigens contact T cell receptors and the functions of lipid reactive T cells in human patients. Specifically, we will use chromatography and mass spectrometry to discover new antigens that bind to each type of CD1 protein and determine the general chemical rules of their recognition. Further, biophysical measurements and protein crystallization will determine the strength and mechanisms of how lipid antigens contact T cell receptors. Using human cells, we will measure the influence of the inflammasome and cytokines in regulating expression of CD1 proteins in dendritic cells and tissues. Last, we will use newly developed cell surface staining reagents to determine the key cytokines and anti-bacterial effector functions of T cells in cohorts of human patients located in Boston and KwaZulu-Natal, South Africa. These studies are relevant to the mission of the NIH because they focus on human subjects with natural diseases so that results can be translated into the clinic. Identification of the molecules necessary to initiate CD1 antigen presentation and T cell activation would allow their development as adjuvants or vaccines. Because experiments measure the general functions of the CD1-antigen-T cell receptor interaction, results would also inform understanding of the pathogenesis of related T cell-mediated diseases like sepsis, Lyme disease, allergic asthma and atherosclerosis.
描述(由申请人提供:M。结核病仍然是全球重要的病原体,目前感染16亿人,每年造成170万人死亡。人类对感染的成功应答关键取决于T细胞,T细胞以前被认为仅由与MHC蛋白结合的肽抗原激活。然而,CD 1蛋白代表了分枝杆菌和其他病原体激活T细胞的新发现途径。CD 1蛋白在树突状细胞上以高度调节的方式表达,在树突状细胞中它们捕获分枝杆菌脂质抗原以呈递给T细胞。CD 1蛋白存在于所有哺乳动物中,因此可能在免疫应答中具有不可或缺的功能。虽然CD 1d和NK T细胞的基本功能已被充分了解,但人CD 1a、CD 1b和CD 1c蛋白的天然功能尚不清楚。在发现由CD 1a(双脱氧分枝杆菌素)、CD 1b(葡萄糖单霉菌酸酯)和CD 1c(甘露糖磷酸菌酮)呈递的脂质抗原后,该更新提案使用了一个开发良好的模型系统,首次确定了这些抗原与T细胞受体接触的一般分子机制以及人类患者中脂质反应性T细胞的功能。具体来说,我们将使用色谱和质谱来发现与每种类型的CD 1蛋白结合的新抗原,并确定其识别的一般化学规则。此外,生物物理测量和蛋白质结晶将确定脂质抗原如何接触T细胞受体的强度和机制。使用人类细胞,我们将测量炎性体和细胞因子在调节树突状细胞和组织中的CD 1蛋白表达中的影响。最后,我们将使用新开发的细胞表面染色试剂来确定位于波士顿和南非夸祖鲁-纳塔尔的人类患者队列中T细胞的关键细胞因子和抗菌效应子功能。这些研究与NIH的使命相关,因为它们关注患有自然疾病的人类受试者,以便结果可以转化为临床。鉴定启动CD 1抗原呈递和T细胞活化所必需的分子将允许它们作为佐剂或疫苗开发。由于实验测量了CD 1-抗原-T细胞受体相互作用的一般功能,因此结果也将有助于了解相关T细胞介导的疾病(如败血症,莱姆病,过敏性哮喘和动脉粥样硬化)的发病机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID Branch MOODY其他文献

DAVID Branch MOODY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID Branch MOODY', 18)}}的其他基金

Chemical Biological Discovery of Lipid Virulence Factors in the Major Bacterial Pathogens
主要细菌病原体中脂质毒力因子的化学生物学发现
  • 批准号:
    10518252
  • 财政年份:
    2022
  • 资助金额:
    $ 44.63万
  • 项目类别:
Chemical Biological Discovery of Lipid Virulence Factors in the Major Bacterial Pathogens
主要细菌病原体中脂质毒力因子的化学生物学发现
  • 批准号:
    10651853
  • 财政年份:
    2022
  • 资助金额:
    $ 44.63万
  • 项目类别:
Profiling and Mapping Core
分析和映射核心
  • 批准号:
    10612026
  • 财政年份:
    2021
  • 资助金额:
    $ 44.63万
  • 项目类别:
Study of M. tuberculosis under human host selection to identify virulence and barrier lipids (Project 1)
研究人类宿主选择下的结核分枝杆菌以确定毒力和屏障脂质(项目 1)
  • 批准号:
    10612035
  • 财政年份:
    2021
  • 资助金额:
    $ 44.63万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10271479
  • 财政年份:
    2021
  • 资助金额:
    $ 44.63万
  • 项目类别:
Profiling and Mapping Core
分析和映射核心
  • 批准号:
    10271480
  • 财政年份:
    2021
  • 资助金额:
    $ 44.63万
  • 项目类别:
Metabolic adaptions of Mycobacterium tuberculosis at diverse host-pathogen interfaces
结核分枝杆菌在不同宿主-病原体界面的代谢适应
  • 批准号:
    10630740
  • 财政年份:
    2021
  • 资助金额:
    $ 44.63万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10612024
  • 财政年份:
    2021
  • 资助金额:
    $ 44.63万
  • 项目类别:
Profiling and Mapping Core
分析和映射核心
  • 批准号:
    10438913
  • 财政年份:
    2021
  • 资助金额:
    $ 44.63万
  • 项目类别:
Metabolic determinants of Mtb virulence, vulnerability and variation
结核分枝杆菌毒力、脆弱性和变异的代谢决定因素
  • 批准号:
    10438911
  • 财政年份:
    2021
  • 资助金额:
    $ 44.63万
  • 项目类别:

相似海外基金

New technologies for targeted delivery of anti-bacterial agents
抗菌药物靶向递送新技术
  • 批准号:
    1654774
  • 财政年份:
    2015
  • 资助金额:
    $ 44.63万
  • 项目类别:
    Studentship
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
  • 批准号:
    8416313
  • 财政年份:
    2012
  • 资助金额:
    $ 44.63万
  • 项目类别:
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
  • 批准号:
    8298885
  • 财政年份:
    2012
  • 资助金额:
    $ 44.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了